MedTrace Logo

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

NCT01468168 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2012-12-17

No results posted yet for this study

Summary

To investigate the safety and efficacy of DE-101 to improve the signs and symptoms in dry-eye disease.

Conditions

Interventions

DRUG

DE-101 Ophthalmic Suspension

Ophthalmic suspension; QID

DRUG

DE-101 Ophthalmic Suspension

Ophthalmic suspension; QID

DRUG

DE-101 Ophthalmic Suspension Vehicle

Ophthalmic suspension vehicle; QID

Sponsors & Collaborators

  • Santen Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468168 on ClinicalTrials.gov